Home/Diasome Pharmaceuticals/Peter Tollman, PhD
PT

Peter Tollman, PhD

Board Member

Diasome Pharmaceuticals

Diasome Pharmaceuticals Pipeline

DrugIndicationPhase
OPTI-2, Injectable HDV-Rapid Acting InsulinType 1 DiabetesPhase 2B
Injectable HDV-Rapid Acting Insulin (Open Label, MoA)DiabetesPhase 2
Injectable HDV-GLP-1, Novel MechanismMetabolic Disease/ObesityPreclinical
Oral HDV-Serotonin, Novel MechanismInsulin Resistance/Metabolic DiseasePreclinical